Literature DB >> 10581836

Overview of phase I surgery for obstructive sleep apnea syndrome.

K K Li1, N B Powell, R W Riley, R Troell, C Guilleminault.   

Abstract

It is well established that obstructive sleep apnea syndrome is associated with increased morbidity and mortality. Surgical therapy has been demonstrated to be a viable treatment option for cure. Thorough presurgical evaluation with the identification of the type of airway abnormality is mandatory to allow for the utilization of a surgical protocol that results in improved clinical outcomes. Phase I surgical protocol is designed to apply specific surgical procedures to alleviate the obstruction(s) present. Following a logical, stepwise surgical approach in airway reconstruction will minimize surgical interventions and avoid unnecessary operations. The incorporation of a risk-management protocol will minimize treatment complications while achieving cure.

Entities:  

Mesh:

Year:  1999        PMID: 10581836

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  4 in total

1.  One stage multilevel surgery (uvulopalatopharyngoplasty, hyoid suspension, radiofrequent ablation of the tongue base with/without genioglossus advancement), in obstructive sleep apnea syndrome.

Authors:  Wietske Richard; Dennis Kox; Cindy den Herder; Harm van Tinteren; Nico de Vries
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-25       Impact factor: 2.503

2.  Multilevel radiofrequency ablation for snoring and OSAHS patients therapy: long-term outcomes.

Authors:  Andrea De Vito; Sabrina Frassineti; Maria Laura Panatta; Filippo Montevecchi; Pietro Canzi; Claudio Vicini
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-28       Impact factor: 2.503

Review 3.  Management of Obstructive Sleep Apnea in Patients With Heart Failure.

Authors:  Youmeng Wang; Christoph Schöbel; Thomas Penzel
Journal:  Front Med (Lausanne)       Date:  2022-02-18

4.  Obstructive sleep apnea - management update.

Authors:  Craig A Hukins
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.